BioCentury | Dec 13, 2018
Company News

Management tracks: Tamura reclaims CEO role at Sosei

Sosei Group Corp. (Tokyo:4565) said Peter Bains will step down as president and CEO and resign as director on Dec. 31. Executive Chairman, founder and former CEO Shinichi Tamura will replace Bains, effective Jan. 1....
BioCentury | Apr 7, 2017
Finance

Fast-growing evergreen

A larger and earlier than expected payout from Ogeda S.A. could substantially increase the size of Fund+’s evergreen life sciences fund, leading the firm to consider broadening its investment strategy. On April 3, Astellas Pharma...
BioCentury | Oct 26, 2016
Financial News

Fund+ closes EUR 125M fund

Fund+ closed its Belgian Life Sciences fund at EUR 125 million ($136.1 million), exceeding its EUR 100 million ($108.9 million) target. Investors included SFPI-FPIM, SRIW, Meusinvest, Spinventure and Sambrinvest, as well as private investors and...
BioCentury | May 19, 2016
Finance

Found in translation

Mark Zipkin, Staff Writer With almost $1 billion in new venture funds in the last year and a half aimed at academic research, Europe is showing signs of a dedicated effort among investors and universities...
BioCentury | Sep 14, 2015
Financial News

Novadip completes venture financing

Novadip Biosciences S.A. , Louvain La Neuve, Belgium Business: Gene/Cell therapy, Musculoskeletal Date completed: 2015-09-10 Type: Venture financing Raised: EUR28 million ($31.2 million) Investors: New Science Ventures; Vives Louvain Technology Fund; Nivelinvest; Fund+; Integrale; Societe Regionale...
BioCentury | Sep 11, 2015
Financial News

Novadip raises EUR 28M in series A

Novadip Biosciences S.A. (Louvain-la-Neuve, Belgium) raised EUR 28 million ($31.2 million) in a series A round led by New Science Ventures. Also participating were VIVES Louvain Technology Fund; Nivelinvest; Fund+; Integrale; SRIW; SFPI-FPIM; Epimede; and...
Items per page:
1 - 6 of 6
BioCentury | Dec 13, 2018
Company News

Management tracks: Tamura reclaims CEO role at Sosei

Sosei Group Corp. (Tokyo:4565) said Peter Bains will step down as president and CEO and resign as director on Dec. 31. Executive Chairman, founder and former CEO Shinichi Tamura will replace Bains, effective Jan. 1....
BioCentury | Apr 7, 2017
Finance

Fast-growing evergreen

A larger and earlier than expected payout from Ogeda S.A. could substantially increase the size of Fund+’s evergreen life sciences fund, leading the firm to consider broadening its investment strategy. On April 3, Astellas Pharma...
BioCentury | Oct 26, 2016
Financial News

Fund+ closes EUR 125M fund

Fund+ closed its Belgian Life Sciences fund at EUR 125 million ($136.1 million), exceeding its EUR 100 million ($108.9 million) target. Investors included SFPI-FPIM, SRIW, Meusinvest, Spinventure and Sambrinvest, as well as private investors and...
BioCentury | May 19, 2016
Finance

Found in translation

Mark Zipkin, Staff Writer With almost $1 billion in new venture funds in the last year and a half aimed at academic research, Europe is showing signs of a dedicated effort among investors and universities...
BioCentury | Sep 14, 2015
Financial News

Novadip completes venture financing

Novadip Biosciences S.A. , Louvain La Neuve, Belgium Business: Gene/Cell therapy, Musculoskeletal Date completed: 2015-09-10 Type: Venture financing Raised: EUR28 million ($31.2 million) Investors: New Science Ventures; Vives Louvain Technology Fund; Nivelinvest; Fund+; Integrale; Societe Regionale...
BioCentury | Sep 11, 2015
Financial News

Novadip raises EUR 28M in series A

Novadip Biosciences S.A. (Louvain-la-Neuve, Belgium) raised EUR 28 million ($31.2 million) in a series A round led by New Science Ventures. Also participating were VIVES Louvain Technology Fund; Nivelinvest; Fund+; Integrale; SRIW; SFPI-FPIM; Epimede; and...
Items per page:
1 - 6 of 6